DK2981258T3 - Farmaceutiske formuleringer til subkutan indgivelse af furosemid - Google Patents

Farmaceutiske formuleringer til subkutan indgivelse af furosemid Download PDF

Info

Publication number
DK2981258T3
DK2981258T3 DK14778339.3T DK14778339T DK2981258T3 DK 2981258 T3 DK2981258 T3 DK 2981258T3 DK 14778339 T DK14778339 T DK 14778339T DK 2981258 T3 DK2981258 T3 DK 2981258T3
Authority
DK
Denmark
Prior art keywords
furosemid
subcutane
administration
pharmaceutical formulations
formulations
Prior art date
Application number
DK14778339.3T
Other languages
Danish (da)
English (en)
Inventor
Scott A Michaels
Pieter Muntendam
Glenn R Larsen
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Application granted granted Critical
Publication of DK2981258T3 publication Critical patent/DK2981258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK14778339.3T 2013-04-05 2014-04-03 Farmaceutiske formuleringer til subkutan indgivelse af furosemid DK2981258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (1)

Publication Number Publication Date
DK2981258T3 true DK2981258T3 (da) 2020-10-19

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14778339.3T DK2981258T3 (da) 2013-04-05 2014-04-03 Farmaceutiske formuleringer til subkutan indgivelse af furosemid

Country Status (14)

Country Link
US (5) US9884039B2 (enExample)
EP (3) EP2981258B8 (enExample)
JP (2) JP6415535B2 (enExample)
KR (2) KR102266460B1 (enExample)
CN (1) CN105431145B (enExample)
AU (1) AU2014248164B2 (enExample)
CA (1) CA2908935C (enExample)
DK (1) DK2981258T3 (enExample)
ES (1) ES2823589T3 (enExample)
IL (1) IL241917B (enExample)
MX (1) MX367165B (enExample)
PT (1) PT2981258T (enExample)
SG (2) SG11201508251RA (enExample)
WO (1) WO2014165660A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
IL300152A (en) * 2020-08-05 2023-03-01 Scpharmaceuticals Inc Methods of treatment using furosemide
WO2022212813A1 (en) 2021-04-02 2022-10-06 Scpharmaceuticals Inc. Subcutaneous infusion of furosemide
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
ES2136090T3 (es) * 1991-05-30 1999-11-16 Abbott Lab Reactivos que contienen un inhibidor de fijacion no especifico para analisis de fijacion con captura de iones.
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
MX340669B (es) * 2008-09-09 2016-07-20 Cima Labs Inc Formas farmaceuticas para compuestos debilmente ionizables.
MX2012002762A (es) * 2009-09-04 2012-06-12 Minipumps Llc Parche cutaneo adhesivo con bomba para suministro subcutaneo de farmacos.
CN103998047A (zh) 2011-10-19 2014-08-20 墨卡托医疗系统公司 局部调节组织和细胞以提高疗效包括肾去神经支配
CN105431145B (zh) 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
ES3058386T3 (es) * 2019-01-04 2026-03-10 Sq Innovation Ag Composiciones farmacéuticas de furosemida
AU2020214314B2 (en) * 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Also Published As

Publication number Publication date
US20160051507A1 (en) 2016-02-25
US20250339397A1 (en) 2025-11-06
JP2016515623A (ja) 2016-05-30
KR20210075211A (ko) 2021-06-22
EP3799869A1 (en) 2021-04-07
MX2015014064A (es) 2017-04-13
US20230201156A1 (en) 2023-06-29
EP2981258B1 (en) 2020-08-12
EP4696308A1 (en) 2026-02-18
ES2823589T3 (es) 2021-05-07
CN105431145B (zh) 2019-12-10
KR102493735B1 (ko) 2023-01-30
US10272064B2 (en) 2019-04-30
JP6415535B2 (ja) 2018-10-31
JP6677779B2 (ja) 2020-04-08
BR112015025204A2 (pt) 2021-03-16
US20180303790A1 (en) 2018-10-25
KR102266460B1 (ko) 2021-06-17
MX367165B (es) 2019-08-07
CN105431145A (zh) 2016-03-23
CA2908935C (en) 2021-06-15
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
HK1221152A1 (zh) 2017-05-26
SG10201709388QA (en) 2017-12-28
US20200038364A1 (en) 2020-02-06
CA2908935A1 (en) 2014-10-09
EP2981258A1 (en) 2016-02-10
AU2014248164B2 (en) 2019-05-23
KR20160014592A (ko) 2016-02-11
EP2981258A4 (en) 2016-10-05
EP3799869B1 (en) 2025-08-27
EP2981258B8 (en) 2020-11-11
AU2014248164A1 (en) 2015-10-15
PT2981258T (pt) 2020-10-19
WO2014165660A1 (en) 2014-10-09
IL241917B (en) 2020-10-29
JP2019001821A (ja) 2019-01-10
US9884039B2 (en) 2018-02-06
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
DK3302638T3 (da) Anordning til indgivelse af lægemidler
HUE040609T2 (hu) GLP-1 vegyületek orális adagolása
DK2968071T3 (da) Enhed til oral levering af terapeutiske forbindelser
DK3139986T3 (da) System til administration af terapeutisk gas
DK3669913T3 (da) Anordning til indgivelse af lægemidler
DK3797742T3 (da) Indretning til suprakoroidal indgivelse af terapeutisk middel
DK3062849T3 (da) Medikamentadministrationsanordning
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
PT3089754T (pt) Formulações de vacina de dose única
IL240797B (en) Oral formulations of deferasirox
DK3023100T3 (da) Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3378482T5 (da) Formulering til administration af antitumorlægemiddel
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
DK3287133T3 (da) Proton-bindende polymerer til oral indgivelse
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3021911T3 (da) Anordning til indgivelse af lægemidler
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
IL241917B (en) Formulations for subcutaneous administration of furosemide
DK2964193T3 (da) Lægemidler til oral indgivelse
EP2987489A4 (en) MEDICINAL FORMULATION WITH DELAYED RELEASE